THE INTERSECTION OF BRAIN SCIENCE & HUMAN POTENTIALPartner with us
neurofeedback.com
The newsletter
← Research & Evidence
MixedProspectively registered double-blind randomized sham-controlled parallel-group trial

Efficacy and Safety of Intensive Continuous Theta Burst Stimulation Over the Right Dorsolateral Prefrontal Cortex in Insomnia Disorder: A Randomized Sham-Controlled Trial

Published November 12, 2026. In this small 30-person trial, active and sham groups both reported large improvements over time. Active stimulation did not outperform sham on the primary Sleep Condition Indicator or on the other sleep-specific measures. Quality of life improved more in the active group, but the study used only self-report outcomes and followed participants for two weeks after treatment. The result is useful mixed evidence, not proof that cTBS treats insomnia.

Garg N, Garg S, Dhyani M.
Primary Care Companion for CNS Disorders · Publication date: 2026-11-12
Added to site: 2026-11-20
DOI: 10.4088/PCC.26m04225

Published online November 12, 2026. Added to Neurofeedback.com November 20, 2026 after comparison with fresh and retained candidates. The source publication date is separate from the site addition date.

Modalities
Continuous theta burst stimulation, Transcranial magnetic stimulation, Noninvasive brain stimulation
Clinical focus
Insomnia disorder, Sleep outcomes, Quality of life and safety
Population
Thirty adults ages 18 to 60 with DSM-5 insomnia disorder who remained on stable psychotropic medication regimens
Sample
30 randomized, 15 per group; the full text reports intention-to-treat mixed-effects analyses
Intervention / method
Active or sham continuous theta burst stimulation targeted the right dorsolateral prefrontal cortex at F4. The protocol delivered 21 sessions of 600 pulses, three sessions per day on seven treatment days within 10 days. Self-reported sleep, sleep-related function and quality of life were assessed at baseline, day 10 and day 25. The registered trial was CTRI/2024/10/075898.
Comparator
Sham continuous theta burst stimulation with the same assessment schedule

Clinician summary

The group-by-time interactions were nonsignificant for the primary SCI, F=2.14, p=.147, and for PSQI, F=3.32, p=.060; ISI, F=0.23, p=.720; and FOSQ-10, F=0.88, p=.388. WHOQOL-BREF favored active cTBS, F=8.92, p=.002, partial eta squared=.242, with mean improvement of 29.07 versus 15.67 points by day 25. Three participants reported transient mild headache, two active and one sham, and no serious adverse event was recorded.

How to interpret the findings

The study randomized only 30 people and was powered for a large effect, not moderate effects. Every participant remained on stable psychotropic medication. Outcomes were self-reported, with no polysomnography or actigraphy. Targeting used the F4 scalp position rather than neuronavigation, and follow-up ended two weeks after treatment. The isolated quality-of-life finding was secondary while all sleep-specific between-group comparisons, including the primary outcome, were null. The data do not establish durable sleep benefit, comparative effectiveness or routine clinical use.

Equipment and disclosures

The source describes cTBS delivery at 80% of resting motor threshold but does not establish superiority for a device or commercial system. No equipment is attributed to BrainMaster or another site sponsor.

The authors reported no financial disclosures and no funding support. They reported using Claude for language editing and manuscript preparation, followed by author review and responsibility for the publication. No correction, retraction or expression-of-concern notice tied to the DOI appeared in the checked PubMed, publisher or bounded DOI and title searches on November 20, 2026; this is not assurance of absence. AI-assisted source review for Neurofeedback.com, not independent human clinical review.

Related evidence

Compare findings from the same clinical area, including mixed results.

Full text checked · Checked 2026-11-20

Summary prepared with AI assistance. Source verification does not imply an independent replication or a clinician's endorsement. Read our review method.